Literature DB >> 33512655

Supporting international networks through platforms for standardised data collection-the European Registries for Rare Endocrine Conditions (EuRRECa) model.

S R Ali1,2, J Bryce2, C Smythe2, M Hytiris1,2, A L Priego3, N M Appelman-Dijkstra3, S F Ahmed4,5,6.   

Abstract

Rare endocrine pathology is manifested by either a deficiency or excess of one or more hormones. These conditions can be life-threatening and are almost universally associated with long-term morbidity. Understanding the aetiology of these conditions requires multicentre collaboration and expertise, most often across national boundaries, with the capacity for long-term follow-up. The EuRRECa (European Registries for Rare Endocrine Conditions) project ( www.eurreca.net ), funded by the EU Health Programme, aims to support the needs of the wider endocrine community by maximising the opportunity for collaboration between patients, health care professionals and researchers across Europe and beyond. At the heart of the EuRRECa collaboration is a Core Endocrine Registry that collects a core dataset for all rare endocrine conditions that are covered within Endo-ERN. The registry incorporates patient reported markers of clinical outcome and will signpost participants to high-quality, disease-specific registries. Furthermore, an electronic surveillance programme (e-REC) captures clinical activity and epidemiology for these rare conditions. EuRRECa receives guidance compliant with the highest ethical standards from Expert Working Groups that align with the Main Thematic Groups of Endo-ERN. Security, data quality and data governance are cornerstones of this platform. Clear policies that are acceptable to patients, researchers and industry for data governance coupled with widespread dissemination and knowledge exchange through closely affiliated stakeholders will ensure sustainability beyond the current lifetime of the project. This paper describes the infrastructure that has been developed, stakeholder involvement, the data fields that are captured within the registry and details on the process for using the platform.

Entities:  

Keywords:  Databases; Endocrinology; European Reference Networks; Rare conditions; Rare diseases; Registries

Mesh:

Year:  2021        PMID: 33512655      PMCID: PMC7844549          DOI: 10.1007/s12020-021-02617-0

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  1 in total

1.  Rare disease surveillance: An international perspective.

Authors:  E J Elliott; A Nicoll; R Lynn; V Marchessault; R Hirasing; G Ridley
Journal:  Paediatr Child Health       Date:  2001-05       Impact factor: 2.253

  1 in total
  3 in total

1.  The Quality Evaluation of Rare Disease Registries-An Assessment of the Essential Features of a Disease Registry.

Authors:  Salma Rashid Ali; Jillian Bryce; Yllka Kodra; Domenica Taruscio; Luca Persani; Syed Faisal Ahmed
Journal:  Int J Environ Res Public Health       Date:  2021-11-15       Impact factor: 3.390

Review 2.  Opportunities and Challenges for Machine Learning in Rare Diseases.

Authors:  Sergio Decherchi; Elena Pedrini; Marina Mordenti; Andrea Cavalli; Luca Sangiorgi
Journal:  Front Med (Lausanne)       Date:  2021-10-05

3.  Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Scleritis.

Authors:  Luca Cantarini; Claudia Fabiani; Francesca Della Casa; Antonio Vitale; Rosa Maria Pereira; Silvana Guerriero; Gaafar Ragab; Giuseppe Lopalco; Marco Cattalini; Irene Mattioli; Paola Parronchi; Maria Pia Paroli; Emanuela Del Giudice; Carla Gaggiano; Marília A Dagostin; Valeria Albano; Mahmoud M Soliman; Sergio Colella; Giuseppe Nascimbeni; Jurgen Sota; Isabele P B Antonelli; Giovanni Alessio; Valeria Caggiano; Abdurrahman Tufan; Rana Hussein Amin; Maria Tarsia; Mahmoud Ghanema; Florenzo Iannone; Francesca Ricci; Francesco La Torre; Ewa Więsik-Szewczyk; Edoardo Conticini; Stefano Gentileschi; Rosanna Dammacco; Rolando Cimaz; Bruno Frediani; Anna Abbruzzese; Piero Ruscitti; Gian Marco Tosi; Heitor F Giordano; Alessandro Conforti; Alberto Balistreri; Donato Rigante
Journal:  Ophthalmol Ther       Date:  2022-01-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.